- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Sprycel
Synonyms :
dasatinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
dasatinib: they may diminish the serum concentration of antacids
dasatinib: they may diminish the serum concentration of antacids
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may enhance the serum concentration of CYP3A4 inhibitors
may increase the hepatotoxic effect of acetaminophen
may diminish the serum concentration of CYP3A4 Inducers
may have an increased hepatotoxic effect when combined with dasatinib
may increase the hepatotoxic effect of acetaminophen
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect CNS Depressants
dasatinib and loperamide are both known to elevate the QTc interval
it may enhance the qtc interval when combined with lofexidine
dasatinib together with cisapride lead to an elevation of the QTc interval
QTc interval is increased both by lenvatinib and dasatinib
may increase the QT-prolonging effect and enhance the risk of ventricular arrhythmias
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dasatinib
when both drugs are combined, there may be an increase in the QTC interval
may increase the QTc interval when combined
It may enhance QTc interval when combined with pentamidine
Aminosalicylic Acid Derivatives
It may enhance the effect of Myelosuppressive Agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
It may enhance QTc interval when combined with perphenazine
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
dasatinib can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
dasatinib: they may increase the anticoagulant effect antiplatelet properties
dasatinib: they may increase the anticoagulant effect antiplatelet properties
when bromazepam and dasatinib are used together, there is a potential reduction in the bromazepam's metabolism
Combining tegafur with dasatinib can reduce tegafur’s metabolism
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of dasatinib
when both drugs are combined, there may be an increased risk or severity of adverse effects
the effect of dasatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, both increase the QTC interval
fedratinib increases the effect of dasatinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
osimertinib and dasatinib, when used simultaneously, increase the QTc interval
may increase the anti-coagulant action of anti-coagulants
may increase the anti-coagulant effect of antiplatelet agents
may increase the risk or severity of toxic effects when combined
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it increases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
Adverse drug reactions:
Frequency defined
>10%
Asthenia
Mouth ulceration
Musculoskeletal pain
Upper respiratory tract infection
Diarrhea
Rash
Paronychia
Stomatitis
Anemia
Cough
Conjunctivitis
Nausea
Hyperbilirubinemia
Dyspnea
Constipation
Dermatitis
Insomnia
1-10%
Skin fissures
Dysgeusia
Skin exfoliation/exfoliative skin reactions
Interstitial lung disease
Keratitis
Chest pain
Fatigue
Vomiting
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: dacomitinib (Rx)
Pronounced: da-sa-tnoib
Why do we use dasatinib?
dasatinib is an anticancer drug used to treat certain types of blood cancer. It blocks an abnormal protein that identifies the signals of the cancer.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
